Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Nicholas Butowski, MD
Headshot of Nicholas Butowski
Nicholas Butowski

Description

Summary

This phase I/Ib trial tests the side effects, best dose, tolerability, and effectiveness of RMC-5552 in treating patients with glioblastoma that has come back (recurrent). RMC-5552 is a type of medicine called an mechanistic target of rapamycin (mTOR) inhibitor. These types of drugs prevent the formation of a specific group of proteins called mTOR. This protein controls cancer cell growth, and the study doctors believe stopping mTOR from forming may help to kill tumor cells.

Official Title

A Phase I/Ib, Open-Label, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

Details

Keywords

Glioblastoma, Recurrent Glioblastoma, Recurrence, RMC-5552

Eligibility

Location

  • UCSF
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Nicholas Butowski, MD
    Dr. Nicholas Butowski is a neuro-oncologist who specializes in brain tumors, neuroimaging, cognitive and rehabilitative neurology, and complementary therapies for neurological disorders. He is director of clinical services in neuro-oncology and a researcher at the Brain Tumor Center.

Details

Status
currently not accepting new patients, but might later
Start Date
Completion Date
(estimated)
Sponsor
Nicholas Butowski
ID
NCT05557292
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 48 study participants
Last Updated